X4 Pharmaceuticals, Inc. (XFOR) News

X4 Pharmaceuticals, Inc. (XFOR): $1.51

-0.20 (-11.70%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add XFOR to Watchlist
Sign Up

Industry: Biotech


Ranked

of 384

in industry

Filter XFOR News Items

XFOR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

XFOR News Highlights

  • XFOR's 30 day story count now stands at 5.
  • Over the past 1 day, the trend for XFOR's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • The most mentioned tickers in articles about XFOR are RNA.

Latest XFOR News From Around the Web

Below are the latest news stories about X4 PHARMACEUTICALS INC that investors may wish to consider to help them evaluate XFOR as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Good morning, investor!

William White on InvestorPlace | September 30, 2022

H.C. Wainwright Sticks to Their Buy Rating for X4 Pharmaceuticals (XFOR)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on X4 Pharmaceuticals (XFOR - Research Report), with a price target of $3.50. The company's shares opened today at $1.25.Ramakanth covers the Healthcare sector, focusing on stocks such as Mediwound, X4 Pharmaceuticals, and ImmunoGen. According to TipRanks, Ramakanth has an average return of -14.7% and a 27.92% success rate on recommended stocks. Currently, the analyst consensus on X4 Pharmaceuticals is a Strong Buy with an average price target of $5.50, implying a 340.00% upside from current levels. In a report released yesterday, Brookline Capital Markets also maintained a Buy rating on the stock with a $6.

Carrie Williams on TipRanks | September 28, 2022

X4 Pharmaceuticals (XFOR) Receives a Buy from B.Riley Financial

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on X4 Pharmaceuticals (XFOR - Research Report) today and set a price target of $7.00. The company's shares opened today at $1.05.Mamtani covers the Healthcare sector, focusing on stocks such as Novavax, Altimmune, and Intercept Pharma. According to TipRanks, Mamtani has an average return of -31.7% and a 19.48% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for X4 Pharmaceuticals with a $5.50 average price target, implying a 423.81% upside from current levels.

Howard Kim on TipRanks | September 27, 2022

Analysts Offer Insights on Healthcare Companies: X4 Pharmaceuticals (XFOR) and Avidity Biosciences (RNA)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on X4 Pharmaceuticals (XFOR – Research Report) and Avidity Biosciences (RNA – Research Report) with bullish sentiments. X4 Pharmaceuticals (XFOR) In a report released today, Leah R. Cann from Brookline Capital Markets maintained a Buy rating on X4 Pharmaceuticals, with a price target of $6.50. The company's shares closed last Tuesday at $1.04, close to its 52-week low of $0.86. According to TipRanks.

Christine Brown on TipRanks | September 27, 2022

X4 Pharma Highlights New Data Supporting Mavorixafor's Broad Potential In Chronic Neutropenia

X4 Pharmaceuticals Inc (NASDAQ: XFOR) announced new data from its Phase 1b trial evaluating the ability of its lead clinical candidate, mavorixafor, to increase the absolute neutrophil count (ANC) in chronic neutropenia (CN) patients as monotherapy or concurrently with injectable granulocyte colony-stimulating factor (G-CSF). People with CN have a lower number of neutrophils, a type of white blood cell, for more than three months. 100% of study participants (n=25) responded to treatment with a s

Yahoo | September 27, 2022

X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN)

100% of study participants (n=25) achieved robust responses to oral mavorixafor 100% of neutropenic participants (n=14) achieved normalized neutrophil counts Robust responses achieved across all CN disorders studied (idiopathic, cyclic, congenital); estimated diagnosed patient population ~ 50,000 in the U.S. Results suggest mavorixafor could be the first oral treatment for CN disorders and has the potential to reduce or replace injectable G-CSF, the current standard of care X4 to host investor w

Yahoo | September 27, 2022

X4 Pharmaceuticals to Host Investor Webinar Highlighting New Mavorixafor Phase 1b Data in Chronic Neutropenia

Webcast to take place on September 27 at 8:00 a.m. ET, followed by live Q&ABOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small-molecule therapeutics to benefit people with diseases of the immune system, today announced that it will host an investor webinar to present and discuss new data from its Phase 1b trial evaluating its lead clinical candidate, mavorixafor, in patients with idiopathic, cy

Yahoo | August 31, 2022

All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy

X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | August 18, 2022

X4 Pharmaceuticals to Present at Canaccord Genuity’s 42nd Annual Growth Conference

BOSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, today announced that management will present a corporate overview at the Canaccord Genuity 42nd Annual Growth Conference being held in Boston, MA, from August 8-11, 2022. Details are as follows: Conference: Canaccord Genuity 42nd Annual Growth Conference Format: Corp

Yahoo | August 8, 2022

X4 Pharmaceuticals (XFOR) Gets a Buy Rating from B.Riley Financial

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on X4 Pharmaceuticals (XFOR – Research Report), with a price target of $7.00. The company's shares closed last Friday at $1.24, close to its 52-week low of $0.86. According to TipRanks.com, Mamtani is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -24.6% and a 28.1% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Lineage Cell Therapeutics, and Madrigal Pharmaceuticals. Currently, the analyst consensus on X4 Pharmaceuticals is a Strong Buy with an average price target of $6.00, which is a 395.

Howard Kim on TipRanks | August 5, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5336 seconds.